Christopher P. Leamon - 01 Nov 2021 Form 4 Insider Report for Fusion Pharmaceuticals Inc.

Role
Chief Scientific Officer
Signature
/s/Maria Stahl as Attorney-in-Fact for Christopher Leamon
Issuer symbol
N/A
Transactions as of
01 Nov 2021
Net transactions value
$0
Form type
4
Filing time
02 Nov 2021, 16:37:20 UTC
Next filing
09 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +218,000 $0.000000 218,000 01 Nov 2021 Common Stock 218,000 $7.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option shall vest and become exercisable on the first anniversary of the grant date and the remainder shall vest and become exercisable in 36 substantially equal monthly installments thereafter.